Evidence map›Paper›PMID 24638850›Full record

ArticleNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2014

Tobacco regulatory science: research to inform regulatory action at the Food and Drug Administration's Center for Tobacco Products.

David L Ashley, Cathy L Backinger, Dana M van Bemmel, Deborah J Neveleff

Abstract read
PubMed Publisher
In one paragraph

Article in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Smoking Topography Characteristics of Very Low Nicotine Content Cigarettes, With and Without Nicotine Replacement, in Smokers With Schizophrenia and Controls.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2016
    Trial
  5. Cognitive effects of very low nicotine content cigarettes, with and without nicotine replacement, in smokers with schizophrenia and controls.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2015
    Trial
  6. Article
  7. Article
  8. Article
  9. Guidance for Addressing Conflicts, Bias, and Growth in Early Career Tobacco Regulatory Science Training Through Mentorship.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2024
    Article
  10. Impact of National Institutes of Health and Food and Drug Administration Tobacco Research Funding: A Bibliometrics Analyses.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2023
    Article
  11. Article
  12. NIH Tobacco Research and the Emergence of Tobacco Regulatory Science.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2022
    Article
  13. Article
  14. Article
  15. A Longitudinal Examination of Behavioral Transitions among Young Adult Menthol and Non-Menthol Cigarette Smokers Using a Three-State Markov Model.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2021
    Article
  16. Article
  17. The Experimental Tobacco Marketplace: Demand and Substitutability as a Function of Cigarette Taxes and e-Liquid Subsidies.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2020
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

David L AshleyOffice of Science, Center for Tobacco Products, U.S. Food and Drug Administration, Rockville, MD.
Cathy L BackingerOffice of Science, Center for Tobacco Products, U.S. Food and Drug Administration, Rockville, MD cathy.backinger@fda.hhs.gov.
Dana M van BemmelOffice of Science, Center for Tobacco Products, U.S. Food and Drug Administration, Rockville, MD.
Deborah J NeveleffOffice of Science, Center for Tobacco Products, U.S. Food and Drug Administration, Rockville, MD.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The U.S. Food and Drug Administration (FDA) promotes the development of regulatory science to ensure that a strong evidence base informs all of its regulatory activities related to the manufacture, marketing, and distribution of tobacco products as well as public education about tobacco product constituents and effects. Toward that end, the FDA's Center for Tobacco Products (CTP) provides funding for research studies with scientific aims that fall within its defined regulatory authority. However, given their traditional biomedical focus on basic and applied research, some researchers may not understand the principles of regulatory science or the types of studies CTP funds. The purpose of this paper is (1) to clarify the definition of regulatory science as a distinct scientific discipline, (2) to explore the role of tobacco regulatory science in order to help researchers understand the parameters and types of research that can be funded by CTP, and (3) to describe the types of research efforts that will inform the FDA's public health framework for tobacco product regulation.

Indexed as

Government RegulationUnited States Food and Drug AdministrationCommerceHumansMarketingPublic HealthResearchSmokingTobacco IndustryTobacco ProductsUnited States

Identifiers

PMID24638850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.